DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20202306

Comparison of oral nifedipine and oral labetalol as a single drug therapy for control of blood pressure in preeclampsia

Alpesh R. Patel, Sneha R. Arora, Jalpa K. Bhatt

Abstract


Background: Worldwide hypertension during pregnancy is a common cause of maternal and fetal morbidity and mortality. Effective control of blood pressure is one of the important steps in management of preeclampsia. Few drugs like nifedipine, labetalol, methyldopa, and hydralazine have acceptable high safety profile during pregnancy.

Methods: In this study 120 antenatal women with non-severe preeclampsia were compared by giving either nifedipine or labetalol as a single drug therapy for control of blood pressure. Various parameters like control of blood pressure, side effects of drugs, gestational age at the time of delivery, mode of delivery, any complication and perinatal outcome were assessed.

Results: In this study authors found that in both group, adequate control of blood pressure was achieved. This study shows slightly higher rate of pre term delivery and LSCS with labetalol and minimal side effects with nifedipine but difference in each group is insignificant.

Conclusions: Labetalol and nifedipine both the drugs are equally effective in reducing blood pressure and any of it can safely be used as a first choice of drug for management of hypertension in preeclampsia and it can be decided as per clinician’s experience and familiarity with drug.


Keywords


Antihypertensive, Labetalol, Nifedipine, Non severe preeclampsia

Full Text:

PDF

References


Ghulmiyyah L, Sibai B. Maternal Mortality from Preeclampsia/Eclampsia. Seminars Perinatol. 20125;36(1):56-9.

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33.

von Dadelszen P, de Campos DA, Barivalala W. Classification of hypertensive disorders of pregnancy. The FIGO Textbook of pregnancy hypertension: an evidence-based guide to monitoring, prevention and management. London: Global Library of Women’s Medicine; 2016:33-61.

APEC guideline: Pre-eclampsia. In: Aabama perinatal excellence collaborative guidelines, Protocol, 2020. Available at: http://apecguidelines.org/guideline/preeclampsia/. Accessed on 10th March 2020.

American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122.

Odigboegwu O, Pan LJ, Chatterjee P. Use of antihypertensive drugs during Preeclampsia. Front Cardio Med. 2018;5:50.

Ganesh SK, Unnikrishnan B, Nagaraj K. Determinants of preeclampsia: a case control study in a district hospital in south India. IJCM. 2010;35(4):502-5.

Hangarga US, Rita D, Harshitha K. Comparative study of labetalol and Nifedipine in management of hypertensive disorders in pregnancy. Int J Reprod Obstet Gynecol. 2017;6:194-7.

Rose DT, Jeyarani P. Comparative study of labetalol and nifedipine in management of non-severe preeclampsia and its fetomaternal outcome. Int J Reprod Contracept Obstet Gynecol. 2019;8(5):2035.

Shekhar S, Sharma C. Oral Nifedipine or intravenous Labetalol for hypertensive emergency in pregnancy: a randomized control trial. Obstet Gynecol. 2013;122(5):1057-63.

Dhali B, Bhattacharya S, Ganguly RP, Bandyopadhyay S, Mondal M, Dutta M. A randomized trial of intravenous labetalol and oral nifedipine in severe pregnancy induced hypertension. Int J Reprod Contracept Obstet Gynecol. 2012;1(1):42-6.